Based upon the subgroup Evaluation, we observed that there was significant heterogeneity regarding mortality, favorable results, and the full therapy efficient rate. Pertaining to mortality, The rationale for heterogeneity within the subgroup of edaravone dexborneol and EDV was primarily attributed to variations in drug dosage. Concerning favorable outcomes, The rationale https://gunnervzapj.madmouseblog.com/13781414/getting-my-what-are-the-best-neuroprotective-drugs-to-work